Chika Chijiwa

Itabashi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Journal: JAAD international

Published: January 21, 2026

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long-Term Treatment With Dupilumab: A Single-Center Retrospective Study.

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long-Term Treatment With Dupilumab: A Single-Center Retrospective Study.

Journal: The Journal of dermatology

Published: August 15, 2025

Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.

Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.

Journal: Experimental dermatology

Published: September 03, 2024

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.

Journal: European journal of dermatology : EJD

Published: July 17, 2024

Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.

Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.

Journal: The Journal of dermatology

Published: February 29, 2024

Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.

Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.

Journal: Experimental dermatology

Published: February 12, 2024

Impact of 1-year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis.

Impact of 1-year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis.

Journal: Experimental dermatology

Published: November 24, 2023

Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: A case report.

Spesolimab improved pustules on the palms and soles that were refractory to tumor necrosis factor inhibitors and interleukin-17 inhibitors in a patient with generalized pustular psoriasis: A case report.

Journal: The Journal of dermatology

Published: October 17, 2023

Serum interleukin-10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.

Serum interleukin-10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.

Journal: The Journal of dermatology

Published: October 10, 2023

Thyroid dysfunction in patients with psoriasis: Higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis.

Thyroid dysfunction in patients with psoriasis: Higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasis.

Journal: The Journal of dermatology

Published: August 20, 2019

Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.

Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.

Journal: The Journal of dermatology

Published: July 10, 2018

Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.

Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.

Journal: The British journal of dermatology

Published: July 10, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026